Other studies [82,83,84,85] in melanoma patients have reported that a higher frequency of circulating central memory T cells (CD4 and CD8) that are CD26-negative [86] is associated with an increased tumor inflammatory profile, with longer survival times, and with clinical response to anti-CTLA-4 treatment. Here, DPP4 is linked to neoplasm.